Search

Search Constraints

You searched for: Author/Creator Cheze, Stéphane

Search Results

1. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. (19th April 2022)

2. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. Issue 4 (6th February 2014)

3. Blood transfusion in hematologic intensive care unit. Issue 2 (11th November 2016)

4. Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia. Issue 8 (3rd August 2015)

5. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis. Issue 8 (August 2015)

6. Increased frequencies of circulating and tumor-resident Vδ1+ T cells in patients with diffuse large B-cell lymphoma. Issue 1 (2nd January 2018)

7. Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux. Issue 12 (8th October 2019)

8. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. (15th January 2016)

9. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM). Issue 5 (22nd April 2022)

10. Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. Issue 12 (22nd August 2016)